Progress in epithelial ovarian carcinoma. Has the outcome been improved?

[1] Landen C.N. Jr., Birrer M.J., Sood A.K.: “Early events in the pathogenesis of epithelial ovarian cancer”. J. Clin. Oncol., 2008, 26, 995.

[2] Annunziata C.M., Azad N., Dhamoon A.S., Whiteley G., Kohn E.C.: “Ovarian cancer in the proteomics era”. Int. J. Gynecol.Cancer, 2008 (suppl 1), 1.

[3] McGuire W.P., Hoskins W.J., Brady M.F. et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[4] Trimble E.L.: “The NIH Consensus Conference on Ovarian Cancer: screening, treatment, and follow-up”. Gynecol. Oncol., 1994, 55 (3 Pt 2), S1.

[5] Loizzi V., Chan J.K., Osann K., Cappuccini F., DiSaia P.J., Berman M.L.: “Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy”. Am. J. Obstet. Gynecol., 2003, 189, 1301.

[6] Walsh C.S., Karlan M.Y.: “Contemporary progress in ovarian cancer screening”. Curr. Oncol. Rep., 2007, 9, 485.

[7] Menczer J.: “Cytoreductive surgery in the treatment of advanced ovarian carcinoma. Some controversial aspects”. Eur. J . Gynaecol. Oncol., 1992, 13, 246.

[8] Crawford S.C., Vasey P.A., Paul J., Hay A., Davis J.A., Kaye S.B.: “Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial”. J. Clin. Oncol., 2005, 23, 8802.

[9] Monk B.J., Disaia P.J.: “What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate”. Int. J. Gynecol. Cancer, 2005, 15 (suppl. 3), 199.

[10] Fung-Kee-Fung M., Oliver T., Elit L., Oza A., Hirte H.W., Bryson P.: “Optimal chemotherapy treatment for women with recurrent ovariancancer”. Curr. Oncol., 2007, 14, 195.

[11] von Gruenigen V.E., Daly B.J.: “Treating ovarian cancer patients at the end of life: when should we stop?”. Gynecol. Oncol., 2005, 99, 255.

[12] Lewin S.N., Buttin B.M., Powell M.A. et al.: “Resource utilization for ovarian cancer patients at the end of life: how much is too much?”. Gynecol. Oncol., 2005, 99, 261.

[13] Le T., Leis A., Pahwa P., Wright K., Ali K., Reeder B.: “Quality-of-life issues in patients with ovarian cancer and their caregivers: a review”. Obstet. Gynecol. Surv., 2003, 58, 749.

[14] Bodurka-Bevers D., Basen-Engquist K., Carmack C.L., Fitzgerald M.A., Wolf J.K., de Moor C. et al.: “Depression, anxiety, and quality of life in patients with epithelial ovarian cancer”. Gynecol. Oncol., 2000, 78, 302.

[15] Barnholtz-Sloan J.S., Schwartz A.G., Qureshi F., Jacques S., Malone J., Munkarah A.R.: “Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades”. Am. J. Obstet. Gynecol., 2003, 189, 1120.

[16] Chan J.K., Cheung M.K., Husain A. et al.: “Patterns and progress in ovarian cancer over 14 years”. Obstet. Gynecol., 2006, 108, 521.

[17] Chan J.K., Fuh K., Shin J.Y., Cheung M.K., Powell C.B., Chen L.M., Kapp D.S., Osann K.: “The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?”. Br. J. Cancer, 2008, 98, 1191.

[18] Panici P.B., Maggioni A., Hacker N. et al.: “Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial”. J. Natl. Cancer Inst., 2005, 97, 560.

[19] SEER: Surveillance, Epidemiology, and End Results Program (computer program). 2003.

[20] Engel J., Eckel R., Schubert-Fritschle G., Kerr J., Kuhn W., Diebold J. et al.: “Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate”. Eur. J. Cancer, 2002, 38, 2435.

[21] Gondos A., Holleczek B., Arndt V., Stegmaier C., Ziegler H., Brenner H.: “Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?”. Ann. Oncol., 2007, 18, 1253.

[22] Heintz A.P.M., Odicino F., Maisonneuve P. et al.: “Carcinoma of the ovary”. Int. J. Gynecol. Obstet., 2003, 83 (suppl. 1), 135.

[23] Barchana M.: Director, Israel National Cancer Registry (personal communication), 2008.